Related Experiment Video

Updated: Nov 3, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting

Lauren M Thorpe1, Haluk Yuzugullu2, Jean J Zhao2

  • 11] Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA. [3] Program in Virology, Harvard Medical School, Boston, Massachusetts 02115, USA.

Nature Reviews. Cancer
|December 24, 2014
PubMed

Insights

Phosphatidylinositol 3-kinases (PI3K) signaling is vital for cell communication and frequently hyperactivated in cancers. This review covers PI3K isoform roles, upregulation mechanisms, and therapeutic targeting strategies for cancer treatment.

Area of Science:

  • Molecular Biology
  • Cellular Signaling
  • Oncology

Background:

  • Phosphatidylinositol 3-kinases (PI3Ks) are key regulators of intracellular signaling pathways.
  • Hyperactivation of PI3K signaling is a common hallmark of human cancers, driving tumor growth and progression.

Purpose of the Study:

  • To review recent advances in understanding the roles of specific PI3K isoforms in normal and oncogenic signaling.
  • To discuss mechanisms of PI3K pathway upregulation in cancer.
  • To evaluate the current and future potential of targeting the PI3K pathway in clinical settings.

Main Methods:

  • Literature review of recent research on PI3K signaling.
  • Analysis of PI3K isoform functions in normal physiology and cancer.
  • Examination of clinical data and ongoing trials for PI3K-targeted therapies.

Main Results:

  • Specific PI3K isoforms play distinct roles in cellular processes and cancer development.
  • Multiple mechanisms contribute to PI3K pathway hyperactivation in various cancers.
  • Targeting the PI3K pathway shows promise but faces challenges in clinical application.

Conclusions:

  • Understanding PI3K isoform-specific functions is crucial for effective cancer therapy.
  • Developing strategies to overcome resistance and improve specificity of PI3K inhibitors is essential.
  • Targeting the PI3K pathway represents a significant area of ongoing research and therapeutic development in oncology.

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.8K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K